Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease1 Ianalumab has the potential to become the first and only targeted treatment...
Hence then, the article about novartis announces both ianalumab phase iii clinical trials met primary endpoint in patients with sjogren s disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease )
Also on site :
- Meta faces $40 bn data privacy penalty
- 'It's a portrait of their actual ancestor': Facial reconstruction of Indigenous man who lived in Ecuador 3,000 years ago shared with his descendants
- CaseBioscience® se připojila k týmu, který od agentury ARPA-H získal grant ve výši až 7,3 milionu dolarů na rozvoj konzervace buněčných terapií při pokojové teplotě